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ABSTRACT   Although post-endoscopic retrograde cholangiopancreatography (ERCP) 
cholangitis (PEC) is not as severe as post-ERCP pancreatitis, this complication should not 
be disregarded. The aim of the present study was to evaluate the efficacy of a temporary 
biliary stent for prevention of PEC. Between April 2011 and May 2017, 190 patients underwent 
complete stone removal in a first session of ERCP at our hospital. Using propensity score 
matching, 72 pairs were enrolled in this study. After common bile duct (CBD) stone removal, the 
endoscopists decided to insert a temporary biliary stent if necessary. The incident rate of PEC 
was significantly lower in the stent group than the no-stent group (1% vs. 11%, p = 0.03). The 
length of hospital stay was also significantly shorter in the stent group than the no-stent group 
(5 days vs. 7 days, p < 0.01). In the stent group, one case had stent migration into the bile duct 
and two cases had a mooring stent at the papilla after 1 month. Multivariate analysis identified 
the pancreatic guide wire technique as a risk factor for PEC. We demonstrated that a temporary 
biliary stent reduced the incidence of PEC significantly and the outcome of its placement 
contributed to shortening the hospital stay. Furthermore, the placement of a temporary biliary 
stent caused fewer adverse effects than expected. Mooring stents were noted in three cases, 
which were confirmed by plain abdominal X-ray, but the patients had no symptoms. In two 
cases, the stent remained in the orifice of the papilla, and in one case it migrated into the CBD. 
All three stents were retrieved by elective endoscopic procedures. In conclusion, a temporary 
biliary stent can reduce the incidence of PEC and shorten the length of hospital stay without 
severe adverse outcomes.  doi：10.11482/KMJ-E202046115　(Accepted on September 11, 2020)
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〈Regular Article〉
INTRODUCTION
   Endoscopic retrograde cholangiopancreatography 
(ERCP) greatly impacts the diagnosis and treatment 
of hepatobiliary and pancreatic diseases. However, 
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that antibiotics can prevent PEC in high risk 
groups, and endoscopic nasobiliary drainage 
(ENBD) could reduce the incidence of PEC and 
the length of hospital stay18，19）. Currently, in 
clinical practice, the placement of biliary stents 
or ENBD catheters is often performed in cases in 
which PEC is considered possible at the time of 
treatment. However, after complete stone removal, 
no certain criteria for whether additional biliary 
drainage is necessary are accepted, and it is done at 
endoscopist’s discretion. Furthermore, the choice of 
which drainage method to employ after complete 
stone removal is at the endoscopist’s discretion, 
and is usually performed with placement of an 
ENBD catheter or biliary stent. However, ENBD is 
uncomfortable for the patient and dislocation often 
happens. When a biliary stent is employed, it is 
necessary to remove it endoscopically. To overcome 
the drawbacks of the present methods, a temporary 
biliary stent that dislodges spontaneously after food 
intake is favorable. The aim of the present study was 
to investigate the efficacy and safety of a temporary 
biliary stent in preventing PEC.
PATIENTS AND METHODS
Patients
   Between April 2011 and May 2017, 2055 
consecutive patients aged ≥ 20 years underwent 
common bile duct (CBD) stone removal at 
Kawasaki General Medical Center. A total of 
190 of these patients who had intact papilla and 
underwent complete stone removal in the first 
session of ERCP were enrolled in this study. 
Our ethical committee approved this study and 
the indication for a temporary stent. The flow 
diagram of patient selection is given in Fig. 1 CBD 
stones were detected and evaluated by computed 
tomography (CT), magnetic resonancecholangio 
pancreatgraphy (MRCP), abdominal ultrasound, 
and/or endoscopic ultrasound (EUS) before ERCP. 
Patients who had concomitant severe pancreatitis or 
ERCP has a high risk of complications and requires 
high technical skill. Some complications result in 
serious morbidities, such as post-ERCP pancreatitis 
(PEP), bleeding, perforation, and cholangitis. The 
total incidence of these complications is reported 
to be 5-10%１－５）.  Of these complications, PEP is 
distinctive and many studies have been performed 
to avoid this morbidity. Previous studies reported 
that the incidence of PEP is 3.1-5.4%１，６，７）. 
The mechanism of PEP is considered to be a 
spasm of the sphincter of Oddi, papillary edema, 
and epithelial injury to the pancreatic duct８，９）. 
Numerous studies have focused on preventing PEP, 
and the administration of rectal indomethacin and 
placement of a pancreatic stent have been reported 
as effective prevention methods.
   Post-ERCP cholangitis (PEC) is also an adverse 
event that cannot be disregarded. PEC is reported 
to occur in 0.8-6.6% of ERCPs５，10－13）. Similar 
to PEP, mechanical stimulation of Vater’s papilla 
by the ERCP procedure evokes a spasm of the 
sphincter of Oddi and papillary edema. The 
resulting biliary stasis and bacterial colonization 
cause PEC. Previous studies have reported that 
pathogenic bacteria in PEC are variable and mixed, 
especially Enterobacteriaceae, such as Escherichia 
coli and Klebsiella spp., Enterococcus spp., and 
Streptococcus spp12，14－16）. However, unlike PEP, 
when PEC occurs, it is often rapidly improved by 
the administration of antibiotics or re-intervention 
to improve biliary stasis. Therefore, most PEC 
cases are not severe. Although the mortality of PEC 
is reported to be 0.3-0.9%11，16）, it can prolong the 
hospital stay and antimicrobial drug administration, 
and require another  endoscopic t reatment . 
Accordingly, PEC is an unnecessary morbidity and 
increases medical cost. 
   The risk factors for PEC are age, history 
of ERCP, hilar biliary obstruction, sphincter 
of Oddi dysfunction (SOD), and hilar biliary 
adenocarcinoma５，17）. Some reports have shown 
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who received a biliary stent before complete stone 
removal were excluded from the study. The patients 
were separated into two groups: stent and no-stent. 
The two groups were compared with respect to 
outcomes. We used propensity score matching to 
reduce selection bias. 
Procedure
   We used a side-viewing endoscope (JF - 260V 
or TJF - 260V; Olympus Co. Ltd., Tokyo, Japan) 
and started cannulation of the bile duct using the 
conventional contrast method. In the case of difficult 
biliary cannulation, we used the pancreatic guide 
wire (PGW) technique, wire-guided cannulation 
(WGC), and precutting papillotomy according to 
the judgement of the endoscopist. The starters were 
trainees and, in difficult cases, the trainer helped 
them (partly or almost completely).
   After CBD access, endoscopic sphincterotomy 
(EST), endoscopic papillary balloon dilation 
(EPBD), or endoscopic papillary large balloon 
dilation (EPLBD) were performed on the papilla 
before extraction of the stones. The stones were 
removed by a retrieval balloon or basket, and 
mechanical lithotripsy was used to crush large 
stones if necessary. Complete stone removal was 
certified by balloon occluded cholangiogram. To 
avoid subsequent obstructive cholangitis due to 
edema of the papilla, a temporary biliary stent was 
deployed in high-risk patients at the endoscopist’s 
discretion. We had no rigid criteria on the temporary 
stent placement. However, we usually deployed 
the temporary stent, when it took a long time to 
complete the endoscopic treatment in difficult 
cases, such as of large stone removal, difficult 
biliary cannulation and so on. The temporary 
biliary stent used in this study was a 5Fr.-5 cm 
Geenen-type pancreatic stent (COOK Co. Ltd., 
Winston Salem, US), which has a flap on one side 
(Fig. 2) but no flap on the side placed in the bile 
All ERCP cases with normal anatomy at our hospital 
from April 2011 to May 2017 
(n=2055)
Cases with CBD stones removed completely
(n=190)
First ERCP cases at our hospital
(n=922)
CBD stone cases 
(n=507)
Repeated ERCP cases at our hospital
(n=1133)
cases other than CBD stone
(n=415)
Cases with incomplete CBD stone 






Figure 1: Flow diagram of patient selection 
Fig. 1. Flow diagram of patient selection 
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duct. Therefore, it cannot anchor in the bile duct 
and drops after starting a meal. After certifying 
complete stone removal, this stent was inserted by 
the over-the-wire technique. In all cases, a blood 
test was performed the next morning to monitor 
for adverse effects of the treatment, and patients 
who were suspected of having complications, such 
as cholangitis or pancreatitis, were followed up 
with blood tests and medical imaging. In the stent 
group, the dislodgement of the deployed stent 
after commencement of a meal was confirmed by 
abdominal X-ray, and if it remained in the CBD 
or gastrointestinal tract 1 month later, endoscopic 
removal was performed. 
Study outcome and definition
   The primary outcome was the incidence rate of 
PEC. Secondary outcomes were length of hospital 
stay, the incidence rate of other adverse events, 
and necessity of re-intervention. In this study, PEC 
included aggravation or no improvement in acute 
cholangitis comparison to the patient’s status before 
treatment. 
   Based on several previous studies, we defined 
PEC as follows excluding other infection or 
PEP12，16，20）: body temperature > 38℃ with upper 
right abdominal pain and/or abnormal blood 
examination (white blood cell [WBC] > 12,000/
μL and C-reactive protein [CRP] > 3.0 mg/dL in 
patients without cholangitis before the procedure; 
WBC elevation and CRP increased by more than 3.0 
mg/dL compared to pre-procedure in patients with 
cholangitis before the procedure). 
   Adverse events were defined by the lexicon for 
endoscopic adverse events by the American Society 
of Gastrointestinal Endoscopy. The endoscopist 
decided to perform re-intervention whenever the 
liver function test and cholangitis did not improve 
enough with conservative treatment. 
Statistical analysis
   Continuous variables were compared between 
two groups using the Mann-Whitney U-test and 
expressed as median and interquartile range 
(IQR). Categorical variables were compared using 
Fisher’s exact test. As a sub-analysis of this study, 
multivariate analysis using Fisher’s exact test for 
categorical variables was carried out to evaluate the 
risk factors for PEC. 
   Propensity score matching analysis was performed 
to reduce the influence of differences in baseline 
characteristics between two groups. Two groups 
were matched using 1:1 nearest neighbor-matching 
without replacement. Rigorous adjustments were 
carried out for the following nine factors: age, 
gender, history of EST, blood examination (WBC, 
a b
Figure 2: Geenen-type pancreatic duct stent
a: Conventional stent with flaps on both sides. b: Temporary stent 
without a flap on the side to be inserted into the common bile duct 
(compare the red circles).
Fig. 2. Geenen-type pancreatic duct stent
a: Conventional stent with flaps on both sides. b: Temporary stent without a flap on the side to be inserted into the 
common bile duct (compare the red circles).
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alanine transaminase [ALT], γ-glutamyltransferase 
[γGT], and CRP), gallbladder stone pancreatitis, 
diverticulum at the peripapillary portion, cannulation 
method, procedure time, and endoscopic procedure 
(EST, EPBD, or EPLBD). 
   All statistical analyses were performed with IBM 
SPSS Statistics version 26 (IBM, Armonk, NY, 




   ERCP was performed in 2055 patients at our 
hospital during the study period. Among these 
patients, 1865 were excluded based on the eligibility 
criteria, and 190 patients were selected for the 
study. A temporal and prophylactic biliary stent 
was deployed in 72 patients (prophylactic stent 
[PS] group) and not deployed in 118 patients (no-
stent [NS] group). Propensity score matching was 
conducted, extracting 144 patients, 72 patients 
for each group. Table 1 provides the patients’ 
demographic data and procedural parameters, 
inc luding gender,  age ,  b lood examinat ion 
(WBC, ALT, γGT, and CRP), gallbladder stone 
pancreatitis,  biliary cannulation time, total 
procedure time, and cannulation technique. Before 
propensity matching score, we found no significant 
baseline parameters except the PGW technique (p = 
0.04). After propensity score matching, we found no 
significant difference among parameters. 
PEC and the length of hospital stay
   Table 2 shows the primary and secondary outcomes 
of both groups after endoscopic stone treatment. 
The incidence rate of PEC was significantly lower 
in the PS group than the NS group (n = 1, 1% vs. n 
= 8, 11%; p = 0.03). All cases of PEC were mild to 
moderate. Among cholangitis patients, seven were 
treated conservatively and four were treated with 
immediate endoscopic re-intervention, including 
biliary stent deployment performed the following 
day. However, no stone was found during the 
procedure. The symptoms related to cholangitis 
Table 1. Baseline characteristics of the study patients
Overall cohort (n=190) Propensity-matched cohort (n=144)
PS group (n=118) NS group (n=72) P value PS group (n=72) NS group (n=72) P value
Age, years 72 (62-85) 75 (66-81) 0.75 72 (62-85) 74 (65-82) 0.59
Sex, male 37 (51%) 62 (53%) 0.88 37 (51%) 39 (54%) 0.87
Diverticular(%) 23 (32%) 47 (40%) 0.28 23 (32%) 23 (32%) 1
WBC 6140 (4797-9292) 7015 (5398-9078) 0.22 6140 (4797-9292) 5960 (5015-7653) 0.73
γ-GT 211 (64-410) 149 (65-351) 0.34 211 (64-410) 188 (67-334) 0.47
ALT 94 (23-214) 61 (23-184) 0.29 94 (23-214) 63 (28-207) 0.65
CRP 0.72 (0.17-3.21) 0.52 (0.15-4.48) 0.79 0.72 (0.17-3.21) 0.47 (0.13-2.32) 0.27
Cannulation time, minutes 3 (1-12) 3 (1-10) 0.95 3 (1-12) 3 (1-9) 0.44
Cannulation method
　PGW 3 (4%) 15 (13%) 0.04 3 (4%) 6 (8%) 0.49
　precut 7 (10%) 13 (11%) 0.49 7 (10%) 5 (7%) 0.76
Procedure
　EST 65 (90%) 108 (92%) 0.8 65 (90%) 66 (92%) 1
　EPBD 3 (4%) 5 (4%) 1 3 (4%) 4 (6%) 1
　EPLBD 16 (22%) 19 (16%) 0.34 16 (22%) 12 (17%) 0.53
　EPS 9 (13%) 21 (18%) 0.41 9 (13%) 11 (15%) 0.81
Procedure time, minutes 27 (19-36) 27 (19-37) 0.94 27 (19-36) 24 (18－38) 0.59
Data are presented as median (interquartile range) or n (%). PS: prophylactic stent, NS: no-stent, 
WBC: white blood cell, ALT: alanine transaminase, γGT: γ-glutamyltransferase, CRP: C-reactive protein, 
PGW: pancreatic guide wire technique, EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilation, 
EPLBD: endoscopic papillary large balloon dilation, EPS: endoscopic pancreatic stent.
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improved after these therapies. The cause of PEC 
in the PS group was inadvertent stent dislocation 
within a day after ERCP, which was confirmed by 
CT the following day. The mean length of hospital 
stay was significantly shorter in the PS group than 
the NS group (5 days vs. 7 days, p < 0.01). 
Adverse events
   Table 2 also provides the other adverse events in 
both groups. We noted no mortality or significant 
differences between the two groups. In the PS 
group, we identified one case of stent migration 
into the bile duct and two cases of stent mooring 
in the orifice of the bile duct 1 month after the first 
treatment, but they had no symptoms. Endoscopic 
stent removal was performed in these patients. 
However, these procedures were conducted 
electively. One case who had stent migration had a 
large duodenal diverticulum beside the papilla. 
Risk factors for PEC in all patients
   Eleven patients (6%) in the cohort were diagnosed 
with PEC. Multivariate analysis for the risk of PEC 
is given in Table 3. The parameters considered 
as the risk factor of PEC were selected based on 
previous studies５，13）. Multivariate analysis showed 
that only PGW technique was a risk factor for PEC. 
DISCUSSION
   Many adverse events after ERCP have long been 
discussed. Although PEP is a major adverse event, 
PEC is also not negligible. We hypothesized that 
edema of the papilla after complete stone removal 
induces PEC due to disturbances in bile juice flow 
by repeated mechanical stimuli with a basket or 
balloon catheter in addition to stone impaction in the 
papilla due to incomplete stone removal. Therefore, 
we expect that a temporary biliary stent may be 
effective for prophylaxis of PEC due to the edema 
in the papilla. Despite the retrospective nature of 
this study, we demonstrated that a temporary biliary 
stent reduced the incidence of PEC significantly 
and the outcome of its placement contributed to 
shortening the hospital stay. Furthermore, the 
placement of a temporary biliary stent caused fewer 
Table 2. Outcomes and adverse events after complete stone removal
Overall cohort (n=190) Propensity-matched cohort (n=144)
PS group (n=72) NS group (n=118) P value PS group (n=72) NS group (n=72) P value
Post-ERCP cholangitis 1 (1%) 10 (8%) 0.09 1 (1%) 8 (11%) 0.03
Length of hospital stay, days 5 (3-7) 6 (4-9) 0.028 5 (3-7) 7 (5-11) < 0.01
Post-ERCP pancreatitis 5 (7%) 6 (5%) 0.83 5 (7%) 4 (6%) 1
Bleeding 1 (1%) 1 (1%) 0.71 1 (1%) 1 (1%) 1
Immediate re-intervention 1 (1%) 3 (3%) 1 1 (1%) 3 (4%) 0.62
Biliary drainage 1 (1%) 3 (3%) 1 1 (1%) 3 (4%) 0.62
Elective re-intervention 3  (4%) － － 3 (4%) － －
Stent migration 1 (1%) － － 1 (1%) － －
Stent mooring 2 (3%) － － 2 (3%) － －
Data are presented as median (interquartile range) or n (%).
PS: prophylactic stent, NS: no-stent,
Table 3. Multivariate analysis of the risk factors for post-ERCP 
cholangitis
HR(95% CI) P value
Age ( > 75 y.o.) 0.65 (0.17-2.50) 0.54
Precut 0.70 (0.10-4.72) 0.71
PGW 11.70 (2.61-52.20) < 0.01
EST 0.68 (0.10-4.68) 0.69
EPBD 3.67 (0.25-54.30) 0.35
EPLBD 2.27 (0.48-10.70) 0.3
Procedure time (>30 min) 1.74 (0.40-7.47) 0.46
CI: confidence interval, PGW: pancreatic guide wire technique, 
EST: endoscopic sphincterotomy, EPBD: endoscopic papillary 
balloon dilation, 
EPLBD: endoscopic papillary large balloon dilation.
121Tanikawa T, et al. : A temporary biliary stent was efficacy for prevention of post-ERCP cholangitis after endoscopic common bile duct stone removal.
adverse effects than expected. 
   Yang et al reported that ENBD could also prevent 
PEC and shorten the length of hospital stay19）. 
ENBD certainly can achieve adequate biliary 
decompression after stone removal. As incomplete 
biliary drainage is one of the risk factors for PEC１）, 
ENBD established a preventive effect. Although 
ENBD has the advantage of prophylaxis for PEC, 
the patients who undergo this procedure suffer from 
discomfort due to placement of the ENBD catheter, 
which is often withdrawn unconsciously by elder 
patients. In contrast, a temporary biliary stent 
could result in almost the same outcome as ENBD 
regarding the prevention of PEC. Furthermore, this 
stent spontaneously drops off within 1 month in 
most cases, and only a few cases require another 
endoscopic intervention. 
   However, we noted some adverse events regarding 
the placement of a temporary biliary stent after 
stone removal. In this study, mooring stents were 
noted in three cases, which were confirmed by plain 
abdominal X-ray, but the patients had no symptoms. 
In two cases, the stent remained in the orifice of 
the papilla, and in one case it migrated into the 
CBD. All three stents were retrieved by elective 
endoscopic procedures. Unfortunately, we could not 
demonstrate why a temporary biliary stent remained 
in the CBD. It likely depended on some anatomical 
cause in each patient. In the stent migration 
case, Vater’s papilla was located in the duodenal 
diverticulum, but we were uncertain if this was the 
cause. The diameters of the employed stents were 
thin. Therefore, there was a possibility of migration 
after EST or EPLBD, though the incidence was not 
higher than expected. Additionally, there was no 
patients diagnosed as recurrent cholangitis due to 
obstruction of temporary biliary stent or reflux of 
duodenal content.
   In this study, we tried to calculate the risk factors 
related to inducing PEC. Multivariate analysis 
showed that only the PGW technique was a 
risk factor for PEC, which is required when an 
endoscopist has difficulty achieving successful 
biliary cannulation in a floppy papilla. Therefore, 
employment of the PGW technique means a 
difficult biliary cannulation, which has the potential 
for difficult stone removal that induces edema of the 
papilla. However, a previous study showed that the 
double guide wire endoscopic technique, in which 
one guide wire is placed in the pancreatic duct, has a 
lower incidence rate of PEC than a control group13）. 
This technique is employed in difficult CBD access 
strategies. In that study, the success rate of CBD 
access was significantly higher in the study group 
than the control group. Consequently, the success 
rate of biliary drainage is also different. Therefore, 
we cannot compare our data and the data from the 
previous study. The procedure and cannulation 
time are expected to be related to the duodenal 
papilla edema. However, the consuming time highly 
depends on endoscopists’ skill, especially regarding 
cannulation time. As participation of a trainee 
was a confounding factor, we did not analyze the 
cannulation time. 
   This study has several limitations, including the 
retrospective nature, small number of cases, being 
a single center study, and uncertain criteria for 
insertion of a temporary biliary stent. Although we 
could safely use this temporary biliary stent without 
adverse events in almost all patients, there may 
be other adverse events that we did not encounter 
during the study period. We should at least avoid 
use it for patients with intradiverticular papilla and 
gastrointestinal obstruction. Therefore, we have to 
consider the stent insertion criteria and a randomized 
trial to determine the risk factors and efficacy of 
temporary drainage for preventing PEC. However, 
it is meaningful that this study demonstrated the 
potential effectiveness of plastic stents to reduce 
PEC.
   In conclusion, we suggest that a temporary 
biliary stent can reduce the incidence of PEC and 
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shorten the length of hospital stay. For patients with 
risk factors for PEC, we may consider aggressive 
insertion of temporary biliary stents. 
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